As per our report, the size of the Latin American Companion Diagnostics Market was worth USD 0.33 billion in 2022 and estimated to be growing at a CAGR of 22.83%, to reach USD 0.93 billion by 2027.
Increasing clinical trials to improve cancer patient diagnosis & treatment in Latin America is a significant factor propelling the market's demand. In addition, the increased adoption of innovative medical procedures, the rising disposable incomes of consumers, and the increasing healthcare infrastructure will fuel the Latin America companion diagnostics market.
Companion diagnostics are in-vitro diagnostics that deliver information about the therapeutic reactions of patients for a specific treatment. Companion diagnostics is a comparatively new branch of diagnostics that is predicted to grow rapidly in the near future. The various advantages it offers have increased its market demand. Companion diagnostics are widely used in lung cancer, breast cancer, etc., to detect cancer mutation. According to WHO, approximately 15 % of cancers were diagnosed in 2012 in low & middle-income countries and 9.6 million deaths in 2018 globally. In 2018, the US Food & Drug Administration published the guidelines for Developing & labeling In Vitro Companion Diagnostic devices for a specific group or classes of oncology therapeutic products.
Increasing demand for personalized medicines, rising occurrence of cancer, and reducing costs of drug development are the key factors fuelling the market's growth for companion diagnostics. Factors such as the growing emphasis on targeted therapies and the attention of pharmaceutical companies on the in-house development of companion diagnostics are also enhancing the market's growth. However, the increasing period of the approval process and the extended development time of companion diagnostics may obstruct the market's growth.
This research report on the Latin American Companion Diagnostics Market has been segmented and sub-segmented into the following categories:
Regionally, the Mexican companion diagnostics market is predicted to dominate the Latin American market and is estimated to continue its dominance during the forecast period.
The Brazilian companion diagnostics market can adopt a new precise medicine & companion diagnostic market than other Latin American countries. Government collaborates with private organizations, research institutes & hospitals for companion diagnostics. Brazil increases its companion diagnostic market by entering into the medical field. Brazil is one of the fastest-growing countries in Latin America due to the potential benefits of companion diagnostic & medicine. Growing molecular pathology & diagnostic technology can boost market growth.
The companion diagnostics market is estimated to exhibit healthy CAGR during the forecast period. Increasing government initiatives for developing a companion diagnostic market are dominating the growth of the Argentina companion diagnostics market. Key market players are focusing on collaboration & strategic acquisition to raise their market value.
The rising number of chronic diseases in the country is fuelling the demand for companion diagnostic tests. Expected need for in vitro diagnostic test adding fuel into Chile companion diagnostic market.
KEY MARKET PLAYERS:
Some of the prominent companies operating in the Latin American companion diagnostics market profiled in this report are Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc., Biogenex Laboratories Inc., Ventana Medical Systems Inc., and Thermo Fisher Scientific Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indications
184.108.40.206 Colorectal Cancer
220.127.116.11 Breast Cancer
18.104.22.168 Lung Cancer
22.214.171.124 Gastric Cancer
5.1.2 Inflammation and Autoimmune Diseases
5.1.3 Cardiovascular Diseases
5.1.4 Central Nervous System Disorders
5.1.5 Virology Diseases
5.2 By Technology
5.2.1 Immuno Histochemistry
5.2.2 Molecular Diagnostics
126.96.36.199 In-Situ Hybridization
188.8.131.52 Real Time PCR
184.108.40.206 Gene Sequencing
6. Geographical Analysis
6.5 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Molecular Inc.
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Roche Molecular Systems Inc.
8.3 Leica Biosystems Nussloch GmbH
8.4 BioMérieux Inc.
8.5 Dako Inc.
8.6 Qiagen Ltd.
8.7 ARUP Laboratories
8.8 Myriad Genetics Inc.
8.9 Biogenex Laboratories, Inc.
8.10 Ventana Medical Systems Inc.
8.11 Thermo Fisher Scientific Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.